Communiqués C4 Therapeutics, Inc.

Actions

CCCC

US12529R1077

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 25/08/2026			Varia. 5j.	Varia. 1 janv.
4,200 ^USD	+2,44%		-1,52%	+119,90%

11/08	C4 Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
18/06	Transcript : C4 Therapeutics, Inc. - Special Call

Communiqués

11/08	C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights	GL
11/08	C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights	AQ
10/08	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
11/06	C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population	GL
20/05	C4 Therapeutics to Participate in Upcoming Conferences	GL
18/05	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
12/05	C4 Therapeutics : Our Corporate Presentation (41bc83)	PU
12/05	C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights	GL
09/04	C4 Therapeutics : Our Corporate Presentation (6ee1ba)	PU
09/04	C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)	GL
25/03	C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma	GL
09/03	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
03/03	C4 Therapeutics : Our Corporate Presentation (d54f12)	PU
26/02	C4 Therapeutics : Our Corporate Presentation (706442)	PU
26/02	C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights	GL
23/02	C4 Therapeutics to Participate in Upcoming March Conferences	GL
23/02	C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma	GL
09/02	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
04/02	C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026	GL
04/02	C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026	AQ
26/01	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	GL
21/01	SEC And DOJ Flex On Life Sciences Insider Trading	AQ
20/01	C4 Therapeutics : Our Corporate Presentation (4d01db)	PU
14/01	C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways	GL
25/11	C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference	GL